AEs and drug-related AEs (F16IL2, BI 836858, or combination) occurring in ≥2 of all treated patients
MedDRA preferred term . | All . | Drug related . | ||
---|---|---|---|---|
Any grade, n (%) . | ≥ Grade 3, n (%) . | Any grade, n (%) . | ≥ Grade 3, n (%) . | |
Any event | 15 (100) | 11 (74) | 15 (100) | 5 (33) |
Nonhematologic adverse events | ||||
Pyrexia | 13 (87) | 0 | 13 (87) | 0 |
Chills | 12 (80) | 0 | 12 (80) | 0 |
Infusion-related reaction | 9 (60) | 0 | 9 (60) | 0 |
Nausea | 9 (60) | 1 (7) | 7 (47) | 0 |
Vomiting | 5 (33) | 1 (7) | 2 (13) | 0 |
Back pain | 4 (27) | 0 | 0 | 0 |
Diarrhea | 4 (27) | 0 | 4 (27) | 0 |
Dyspnea | 4 (27) | 1 (7) | 3 (20) | 1 (7) |
Fatigue | 4 (27) | 0 | 3 (20) | 0 |
Edema peripheral | 4 (27) | 0 | 2 (13) | 0 |
Pain in extremity | 4 (27) | 1 (7) | 1 (7) | 0 |
Abdominal pain | 3 (20) | 1 (7) | 1 (7) | 0 |
Cough | 3 (20) | 1 (7) | 1 (7) | 1 (7) |
Decreased appetite | 3 (20) | 1 (7) | 1 (7) | 0 |
Rash | 3 (20) | 1 (7) | 2 (13) | 0 |
Acute GVHD in intestine | 2 (13) | 0 | 1 (7) | 0 |
Alanine aminotransferase increased | 2 (13) | 0 | 2 (13) | 0 |
Aspartate aminotransferase increased | 2 (13) | 0 | 2 (13) | 0 |
Blood bilirubin increased | 2 (13) | 1 (7) | 2 (13) | 1 (7) |
Chest discomfort | 2 (13) | 0 | 1 (7) | 0 |
Epistaxis | 2 (13) | 0 | 0 | 0 |
γ-Glutamyltransferase increased | 2 (13) | 1 (7) | 2 (13) | 1 (7) |
Headache | 2 (13) | 0 | 2 (13) | 0 |
Hypersensitivity | 2 (13) | 0 | 0 | 0 |
Hypoalbuminemia | 2 (13) | 0 | 2 (13) | 0 |
Hypokalemia | 2 (13) | 2 (13) | 1 (7) | 1 (7) |
Hypophosphatemia | 2 (13) | 1 (7) | 2 (13) | 1 (7) |
Hypotension | 2 (13) | 1 (7) | 1 (7) | 0 |
Influenza-like illness | 2 (13) | 0 | 2 (13) | 0 |
International normalized ratio increased | 2 (13) | 0 | 2 (13) | 0 |
Pain neck | 2 (13) | 0 | 1 (7) | 0 |
Stomatitis | 2 (13) | 1 (7) | 0 | 0 |
Syncope | 2 (13) | 2 (13) | 0 | 0 |
Hematologic AEs | ||||
Platelet count decreased | 7 (74) | 5 (33) | 4 (27) | 2 (13) |
Anemia | 3 (20) | 2 (13) | 1 (7) | 1 (7) |
Febrile neutropenia | 3 (20) | 3 (20) | 1 (7) | 1 (7) |
Neutrophil count decreased | 2 (13) | 2 (13) | 2 (13) | 2 (13) |
MedDRA preferred term . | All . | Drug related . | ||
---|---|---|---|---|
Any grade, n (%) . | ≥ Grade 3, n (%) . | Any grade, n (%) . | ≥ Grade 3, n (%) . | |
Any event | 15 (100) | 11 (74) | 15 (100) | 5 (33) |
Nonhematologic adverse events | ||||
Pyrexia | 13 (87) | 0 | 13 (87) | 0 |
Chills | 12 (80) | 0 | 12 (80) | 0 |
Infusion-related reaction | 9 (60) | 0 | 9 (60) | 0 |
Nausea | 9 (60) | 1 (7) | 7 (47) | 0 |
Vomiting | 5 (33) | 1 (7) | 2 (13) | 0 |
Back pain | 4 (27) | 0 | 0 | 0 |
Diarrhea | 4 (27) | 0 | 4 (27) | 0 |
Dyspnea | 4 (27) | 1 (7) | 3 (20) | 1 (7) |
Fatigue | 4 (27) | 0 | 3 (20) | 0 |
Edema peripheral | 4 (27) | 0 | 2 (13) | 0 |
Pain in extremity | 4 (27) | 1 (7) | 1 (7) | 0 |
Abdominal pain | 3 (20) | 1 (7) | 1 (7) | 0 |
Cough | 3 (20) | 1 (7) | 1 (7) | 1 (7) |
Decreased appetite | 3 (20) | 1 (7) | 1 (7) | 0 |
Rash | 3 (20) | 1 (7) | 2 (13) | 0 |
Acute GVHD in intestine | 2 (13) | 0 | 1 (7) | 0 |
Alanine aminotransferase increased | 2 (13) | 0 | 2 (13) | 0 |
Aspartate aminotransferase increased | 2 (13) | 0 | 2 (13) | 0 |
Blood bilirubin increased | 2 (13) | 1 (7) | 2 (13) | 1 (7) |
Chest discomfort | 2 (13) | 0 | 1 (7) | 0 |
Epistaxis | 2 (13) | 0 | 0 | 0 |
γ-Glutamyltransferase increased | 2 (13) | 1 (7) | 2 (13) | 1 (7) |
Headache | 2 (13) | 0 | 2 (13) | 0 |
Hypersensitivity | 2 (13) | 0 | 0 | 0 |
Hypoalbuminemia | 2 (13) | 0 | 2 (13) | 0 |
Hypokalemia | 2 (13) | 2 (13) | 1 (7) | 1 (7) |
Hypophosphatemia | 2 (13) | 1 (7) | 2 (13) | 1 (7) |
Hypotension | 2 (13) | 1 (7) | 1 (7) | 0 |
Influenza-like illness | 2 (13) | 0 | 2 (13) | 0 |
International normalized ratio increased | 2 (13) | 0 | 2 (13) | 0 |
Pain neck | 2 (13) | 0 | 1 (7) | 0 |
Stomatitis | 2 (13) | 1 (7) | 0 | 0 |
Syncope | 2 (13) | 2 (13) | 0 | 0 |
Hematologic AEs | ||||
Platelet count decreased | 7 (74) | 5 (33) | 4 (27) | 2 (13) |
Anemia | 3 (20) | 2 (13) | 1 (7) | 1 (7) |
Febrile neutropenia | 3 (20) | 3 (20) | 1 (7) | 1 (7) |
Neutrophil count decreased | 2 (13) | 2 (13) | 2 (13) | 2 (13) |
MedDRA, Medical Dictionary for Regulatory Activities; drug related refers to F16IL2, BI 836858, or the combination of both.